Clinical Trial Update: Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults [Phase 2]

View source ↗

Summary

Phase 2 safety, tolerability, and immunogenicity study of three prime-boost regimens for Ebola vaccines Ad26.ZEBOV/MVA-BN-Filo in healthy adults, children, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ad26.ZEBOV/MVA-BN-Filo

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Hemorrhagic Fever, Ebola | Phase 2 | Status: COMPLETED | Results posted: 2022-03-07